---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-24-000032"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:40:37.746274+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly Q4 revenue up 28% to $9.35B; EPS $2.42 reported, $2.49 non-GAAP; FY2024 guidance issued

## Summary
- Q4 revenue $9,353.4M (+28% YoY); reported EPS $2.42 (+13%); non-GAAP EPS $2.49 (+19%).
- New Products (Mounjaro, Zepbound) generated $2.49B revenue, up $2.19B YoY; Growth Products $5.27B (+9%).
- 2024 guidance: revenue $40.4–41.6B; EPS $11.80–12.30; non-GAAP EPS $12.20–12.70.
- Pipeline: Zepbound and Jaypirca approved; tirzepatide Phase 2 NASH met primary endpoint; Verzenio Phase 3 mCRPC failed.
- Acquisitions of POINT Biopharma and Mablink Biosciences closed; dividend raised 15% for 6th consecutive year.

## SEC filing metadata
- accession: 0000059478-24-000032
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/0000059478-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/lly-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-24-000032
- JSON: https://secwatch.observer/filing/0000059478-24-000032.json
- Plain text: https://secwatch.observer/filing/0000059478-24-000032.txt

## Key facts
- Earnings Releases
  ELI LILLY & Co reported the quarter and year ended December 31, 2023 results: revenue $9,353.4, net income 2,189.6, EPS 2.42. Guidance initiated.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $9,353.4
  - Net income: 2,189.6
  - EPS: 2.42
  - Guidance: initiated
  - Result: reported results
  source text: on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data Fourth Quarter 2023 2022 % Change Revenue $ 9,353.4 $ 7,301.8 28% Net income – Reported 2,189.6 1,937.7 13% Earnings per share – Reported 2.42 2.14 13% Net income – Non-GAAP 2,249.4 1,893.1 19% Earnings per share – Non-GAAP 2.49
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/0000059478-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.